Eileen A. Elliott, Ph.D., is Executive Director, Scientific Affairs & External Partnership and Kendall Square Site Lead at Pfizer. In this role, she leads the strategy for external outreach, communications, colleague engagement, and site affairs at Pfizer’s Worldwide Research, Development, and Medical (WRDM) campus in Cambridge, Mass., and is a core member of the WRDM Operations leadership team. Eileen joined Pfizer in 1995 as a Research Scientist in Immunology and has held positions of increasing responsibility during her nearly 30-year tenure with the company, including multiple research-focused leadership roles at Pfizer’s WRDM site in Groton, Conn.
Throughout her career at Pfizer, Eileen has made pivotal contributions to drug discovery and the company’s business operations, including leading the discovery and development of both small and large molecules for a range of therapeutic targets. A lead contributor to Xeljanz, Pfizer’s JAK3 modulator, and a co-founder of Alexion’s Solaris product, Eileen has more than 25 peer-reviewed publications and has delivered numerous scientific presentations. She earned her Ph.D. in Immunology from Albany Medical College and completed her postdoctoral fellowship in Dr. Richard Flavell’s laboratory at Yale University as a Howard Hughes Fellow. Eileen is a board member of MassBio and the Kendall Square Association.